Scott Robinson, 51, of Pace, Florida, pleaded guilty on Mar. 11 in federal court to two counts of drug adulteration related to the sale of animal drugs. The announcement was made by John P. Heekin, United States Attorney for the Northern District of Florida.
The case highlights the importance of compliance with federal regulations designed to ensure the safety and integrity of medications sold in the United States. According to U.S. Attorney Heekin, “Complying with federal laws that are in place to ensure the safety of regulated medications is not optional. This defendant knowingly flouted those requirements for several years, but thanks to the excellent investigative work of our federal law enforcement partners, his scheme has been dismantled.”
Court documents show that between 2022 and 2025, Robinson used his website to advertise and sell toltrazuril, an animal drug considered adulterated under the Federal Food, Drug, and Cosmetic Act due to specific production and labeling requirements. The Federal Bureau of Investigation conducted multiple undercover purchases from Robinson’s website; subsequent testing by the Food and Drug Administration confirmed that these products contained toltrazuril. Authorities said Robinson did not comply with FDA regulations regarding production or labeling.
Robinson faces up to one year in prison for each count and a term of supervised release following any incarceration. Sentencing is scheduled for May 21 at the United States Courthouse in Pensacola before United States District Judge T. Kent Wetherell II.
The investigation was conducted by both the Federal Bureau of Investigation and the U.S. Food and Drug Administration. Assistant United States Attorney Christopher C. Patterson is prosecuting the case.
The United States Attorney’s Office for the Northern District of Florida serves as one of 94 offices nationwide under direction from the Attorney General.
